Test Price
2,800 AED✅ Home Collection Available
MYH14 Gene Deafness (Autosomal Dominant Type 4) Genetic Test in UAE
Executive Summary & Core Metrics
Executive Summary
This advanced genetic test delivers comprehensive analysis of the MYH14 gene for autosomal dominant nonsyndromic hearing loss (DFNA4) using next-generation sequencing with 99.9% diagnostic sensitivity. Performed at our ISO 9001:2015 certified facility, the test provides full coding region coverage with deep NGS to detect pathogenic variants, including single nucleotide variants, small insertions or deletions, and copy number variants. VIP Mobile Phlebotomy and Temperature-Controlled Cold-Chain Home Collection is available daily from 8 AM to 11 PM for standard peripheral whole blood specimens. Post-test telephonic genetic counselling and direct insurance verification are accessible via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The MYH14 gene encodes a myosin heavy chain protein essential for the structural integrity and function of inner ear hair cells. Pathogenic variants in MYH14 cause autosomal dominant nonsyndromic hearing loss type 4 (DFNA4), a bilateral, progressive, post-lingual sensorineural hearing loss that typically manifests in early to mid-adulthood. This NGS-based test interrogates the entire coding region and conserved splice sites with deep coverage, enabling detection of clinically actionable variants that conventional Sanger sequencing may miss due to allelic heterogeneity or large rearrangement events.
| Feature | Our Test | Closest Alternative (Sanger Single Gene) |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity, full gene coverage with deep NGS | ~90% sensitivity, may miss deep intronic or large rearrangements |
| Method | Next-Generation Sequencing (NGS) with target enrichment, ISO 15189-compliant bioinformatics | Capillary electrophoresis (Sanger), limited to known exons |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
"This NGS-based test provides definitive molecular confirmation for MYH14-related hearing loss and enables cascade screening for at-risk family members. However, genotype-phenotype correlations require integration with comprehensive audiological data and family history. Pre- and post-test genetic counselling is strongly advised to ensure accurate interpretation and informed reproductive decision-making." – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory
Patients must continue all prescribed hearing amplification devices, aural rehabilitation therapies, and medical treatments as directed by their ENT specialist or audiologist. This genetic test does not replace regular audiological surveillance or clinical ENT evaluation. Do not alter or discontinue any medication without consulting your treating physician.
Safety & Exclusion Criteria
- This test is not indicated for individuals with active acute ear infection, sudden sensorineural hearing loss of unknown etiology, or acute vertigo – immediate ENT evaluation is required.
- Emergency red flags: Sudden profound hearing loss, vertigo with dizziness, severe tinnitus – proceed to the nearest emergency department without delay.
- Not recommended as a standalone diagnostic tool for syndromic hearing loss presentations; comprehensive genetic counselling and syndromic evaluation are necessary.
- For minors, parental or legal guardian consent is mandatory in accordance with UAE regulatory requirements.
Patient FAQ & Clinical Guidance
1. What does the MYH14 gene test detect?
This test identifies pathogenic variants in the MYH14 gene associated with autosomal dominant progressive sensorineural hearing loss (DFNA4). A positive result can confirm a clinical diagnosis, inform prognosis, guide family screening, and support reproductive counselling. The test detects single nucleotide variants, small insertions or deletions, and copy number variants across the entire coding region and splice sites.
2. Who should consider this genetic test?
Individuals with early-onset or progressive bilateral sensorineural hearing loss and a documented family history of deafness should consider this test. A referral from an ENT specialist or clinical geneticist is strongly recommended before testing. The test is also appropriate for asymptomatic adult family members of a known MYH14 variant carrier who seek clarification of their own carrier status.
3. How is the sample collected and what preparation is required?
A standard peripheral whole blood sample (EDTA tube), extracted DNA, or a dried blood spot on an FTA card is collected by a trained phlebotomist during VIP Mobile Phlebotomy home collection. No fasting, dietary restriction, or special preparation is required. The sample is transported under temperature-controlled cold-chain conditions to ensure nucleic acid integrity.
UAE Regulatory & Data Privacy Adherence
Trust & Compliance Framework
This laboratory service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing safety, patient consent, and medical liability procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Our facility maintains ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and operates under the regulatory oversight of the Dubai Health Authority (DHA) and the Ministry of Health and Prevention (MOHAP). Genetic data handling follows strict confidentiality protocols with encrypted storage and restricted access controls.
Clinical & Logistical Metadata
| Test Name | MYH14 Gene Deafness (Autosomal Dominant Type 4) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Extracted DNA, or FTA Card Blood Spot |
| Methodology Used | Next-Generation Sequencing (NGS) with Target Enrichment and ISO 15189-Compliant Bioinformatics |
| ICD-10-CM Code | Z15.89, H90.3, Z13.71 |
| LOINC Code | 81248-4 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians